Celling Biotechnology Co., Ltd, a Guangzhou-based biopharmaceutical company, has announced that its pipeline candidate CEL001 has received tacit clinical trial approval in China. The drug candidate is an antibody fusion protein targeting PD-1, TIGIT, and IL-15, and is intended for the treatment of advanced solid tumors, with a particular focus on digestive tract cancers, including advanced colorectal cancer .
CEL001 is a universal off-the-shelf natural killer (NK) cell therapy that does not require genetic modification. It is characterized by high expression of activating receptors, granzyme, perforin, and exhibits robust cytokine secretion function and cell killing effect. The therapy has shown promising results in preclinical studies, demonstrating the potential to enhance the immune response against cancer cells by leveraging the body’s own NK cells .
The tacit approval by Chinese authorities allows Celling Biotechnology to proceed with clinical studies to further evaluate the safety and efficacy of CEL001. This development marks a significant milestone for the company as it aims to bring this innovative cancer therapy to patients in China and potentially globally.
Celling Biotechnology is positioning CEL001 as a first-in-class treatment, highlighting the growing interest in NK cell-based therapies as a new frontier in cancer treatment. The company’s advancement in the clinical development of CEL001 reflects the dynamic and innovative landscape of China’s biopharmaceutical sector, showcasing the potential for Chinese companies to contribute significantly to the global oncology space.- Flcube.com
